CROs/Service Providers

Parexel launches active tracking service

Thursday, October 6, 2016

Parexel International, a global biopharmaceutical services organization, has launched its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites.

[Read More]

QuintilesIMS merger completed

Tuesday, October 4, 2016

Quintiles IMS Holdings has successfully completed its merger of equals transaction between IMS Health Holdings and Quintiles Transnational Holdings. The merger of IMS Health, a global information and technology services company, and Quintiles, a provider of product development and integrated healthcare services, creates an information and tech-enabled healthcare service provider with global scale and reach, and a full suite of end-to-end clinical and commercial offerings.

[Read More]

PathoQuest partners with Charles River Laboratories

Friday, September 30, 2016

PathoQuest, a rapidly growing biotechnology company spun out from Institut Pasteur, has announced a preferred partnership with Charles River Laboratories, an early-stage CRO, to provide an improved Viral Safety Service offering to biopharmaceutical companies. While traditional molecular approaches to safety testing are limited to the identification of a limited, predefined list of viruses, the PathoQuest’s next generation sequencing (NGS) solution combines a proprietary curated virus database with an automated analysis pipeline. This provides a universal test for identifying viruses of any type in a single, comprehensive analysis that minimizes false negatives.

[Read More]

Charles River Laboratories acquires Agilux Laboratories for $64 million

Thursday, September 29, 2016

Charles River Laboratories International has acquired Agilux Laboratories, a Worcester, Massachusetts-based CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services and pharmacology services. The company’s unique combination of early-stage services enhances the flexibility and speed of its biopharmaceutical clients’ lead identification, optimization, and candidate selection efforts. Agilux was acquired from a holding company controlled by the company’s founders and Ampersand Capital Partners, its only institutional investor.

[Read More]

Parexel to acquire ExecuPharm

Monday, September 26, 2016

Parexel International, a global biopharmaceutical services provider, has entered into a definitive agreement to acquire ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is expected to close in the next three weeks. Terms of the transaction were not disclosed.

[Read More]

Thermo Fisher Scientific opens new clinical services facility in South Korea

Monday, September 12, 2016

To address the growing global demand for clinical services, Thermo Fisher Scientific has announced the official opening of its new state-of-the-art GMP1 standard facility in South Korea. Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies—from cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.

[Read More]

Survey: Significant improvements in inspection readiness among CROs

Thursday, September 8, 2016

Veeva Systems has unveiled the results of the Veeva 2016 Paperless TMF Survey: CRO Report. The global industry survey of trial master file (TMF) owners shows growing use of electronic trial master file (eTMF) solutions among CROs as a result of benefits in audit and inspection readiness. In addition, findings reveal that CROs are leading the drive toward active TMF management and making strides in the use of performance metrics and data to improve the efficiency and speed of clinical trials.

[Read More]

Biorasi joins GPhA Biosimilar Council

Wednesday, September 7, 2016

Biorasi, a CRO that optimizes trial design and delivery for sponsor organizations, is now an associate member organization of the Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA). This newly minted alliance provides Biorasi with the opportunity to work with the world’s leading-edge biosimilar developers, helping to influence policies, form best practices, and promote science-based research and findings related to biosimilar drugs. 

[Read More]